Shares of Replimune Group Inc. (REPL) are down nearly 50% from their 52-week high of $17, recorded last November, and trade around $8.
This clinical-stage biotech company is developing innovative oncolytic immunotherapies using a proprietary HSV-1 strain and immune-activating transgenes to enhance T-cell stimulation and systemic immune response. Its lead investigational product is RP1, which is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and a monomeric glycoprotein (GM-CSF) intended to maximize tumor-killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.